Can a heart failure drug help treat long COVID symptoms?

 

• Some people who have recovered from COVID-19 experience ongoing symptoms — such as brain fog, increased heart rate, and chronic fatigue — sometimes known as long COVID.
• There is an overlap between the symptoms of long COVID and postural orthostatic tachycardia syndrome (POTS), which has led some researchers to suggest they are related.
• A small clinical trial suggests that ivabradine, a drug approved for use in heart failure, may be an effective treatment for POTS, with fewer side effects than existing treatments.

An estimated 1–3 million people in the United States have POTS, which causes tachycardia — a rapid heart rate of more than 100 beats per minute — when a person stands up.

Other common symptoms include:

• poor concentration, or brain fog
• lightheadedness, dizziness, or fainting
• blurred vision
• palpitations
• nausea
• tiredness

The condition predominantly affects females between the ages of 15 and 50, but males can develop it as well.

Patients are often fit and active before they develop POTS. At its worst, the condition can be debilitating and life changing.

POTS affects the body’s autonomic nervous system, which exerts involuntary control over bodily functions, such as heart rate, blood pressure, sweating, and temperature.

Its causes are poorly understood, but the condition often follows a viral infection, trauma, major surgery, or pregnancy.

There is a distinct overlap between the common symptoms of long COVID and POTS. This has led some researchers to propose that the new coronavirus, which can affect the central nervous system, may trigger POTS in some people.

Limitations of current treatment

While the Food and Drug Administration (FDA) have not approved any treatments for POTS, doctors often prescribe beta-blockers to patients with POTS to lower their heart rate.

The drugs reduce activity in the sympathetic nervous system, which is the wing of the autonomic nervous system that reacts to perceived threats with fight-or-flight responses, such as increased heart rate.

However, a drawback of beta-blockers is that they not only reduce heart rate but also lower blood pressure, which can exacerbate patients’ fatigue and lack of energy.

One promising alternative is ivabradine a heart failure drug that slows the heart without reducing blood pressure.

In the first randomized controlled trial of ivabradine for POTS, researchers at the University of California (UC), San Diego, found that the drug significantly reduced heart rate and improved patients’ quality of life 1 month after treatment started.

They report that the drug was well tolerated and that there were no severe side effects.

The research appears in the Journal of the American College of Cardiology.

“Ivabradine is a novel agent that’s FDA-approved for heart failure, but based on its mechanism, we thought it could be helpful for patients with POTS, as it reduces heart rate without impacting blood pressure,” said first author Dr Pam Taub a cardiologist at UC San Diego Health and associate professor of medicine at UC San Diego School of Medicine.

“When we can lower the heart rate, we’re providing these patients with the ability to stand up, something they couldn’t do without difficulty before due to their POTS diagnosis,” she added.

 Source: Medical News Today